Indinavir (Crixivan) Research
- Literature Citations for Indinavir (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Indinavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO - High Dose of Vitamin C Significantly Reduces Indinavir Levels in Pilot Study (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - "Mono"-Therapy for HIV Infection Using Ritonavir-Boosted Indinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Indinavir or Boosted Indinavir? (March 2002)
In Project Inform Perspective, from Project Inform - Ingrown Toenails Still a Possible Side Effect (November 2001)
Indinavir-ritonavir interaction is possible culprit.
In HIV Treatment ALERTS!, from The Center for AIDS - A Phase IV Randomized Open-Label Multicenter Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs. Saquinavir/Ritonavir (1,000/100 mg BID) in Adult HIV-1 Infection: The Max Cmin 1 Trial (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - High Blood Pressure With Indinavir (May 25, 2001)
From Canadian AIDS Treatment Information Exchange - Protease Combinations: Ritonavir and Indinavir One Year Later (March 15, 2001)
Developments from the 8th Conference on Retroviruses and Opportunistic Infections.
From Canadian AIDS Treatment Information Exchange - ACTG 5056: Metabolic Status and Cardiovascular Disease Risk for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir-Containing Regimen (ACTG 372A) (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Preliminary Results From Indinavir (IDV) and Ritonavir (RTV) in a Once-Daily Regimen (Marck 103/104) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate
An ATHENA cohort study found that the use of indinavir significantly increases a person's risk of developing problems like kidney stones -- especially if they are underweight or live in warm areas.
In Archives of Internal Medicine - Indinavir Concentrations Plummet When Coadministered With Rifampicin (February 2004)
From International Association of Physicians in AIDS Care
Clinical Management
Clinical Management
  |